Less weight gain and hypoglycaemia with once-daily insulin detemir than with NPH insulin in basal-bolus therapy of overweight type 2 diabetes patients: The PREDICTIVE-BMT trial

被引：0

作者：

Montanana, C. Fajardo

Herrero, C. Hernandez

Fernandez, M. Rivas

机构：

[1] Hosp Virgen Macarena, Seville, Spain

[2] Hosp Infantil Luisa, Seville, Spain

来源：

DIABETOLOGIA | 2007年 / 50卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0978

引用

页码：S404 / S404

页数：1

共 50 条

[1] Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients -: The PREDICTIVE™ BMI clinical trial
Montanana, C. Fajardo
Herrero, C. Hernandez
Fernandez, M. Rivas
DIABETIC MEDICINE, 2008, 25 (08) : 916 - 923
[2] Insulin detemir is associated with less weight gain than NPH insulin, especially in the very obese, when used in basal bolus therapy for patients with type 2 diabetes
Raslova, K
Karl, D
Tamer, SC
DIABETOLOGIA, 2005, 48 : A306 - A306
[3] Once-daily insulin detemir added to oral antidiabetic drugs results in less weight gain and a trend for reduced hypoglycaemia in comparison to NPH insulin in Japanese patients with type 2 diabetes
Tajima, N.
Iwamoto, Y.
Kaku, K.
Kawamori, R.
Nishida, T.
Kobayashi, M.
DIABETOLOGIA, 2006, 49 : 609 - 609
[4] Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin
De Leeuw, I
Vague, P
Selam, JL
Skeie, S
Lang, H
Draeger, E
Elte, JWF
DIABETES OBESITY & METABOLISM, 2005, 7 (01): : 73 - 82
[5] Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index
Rašlová K.
Tamer S.C.
Clauson P.
Karl D.
Clinical Drug Investigation, 2007, 27 (4) : 279 - 285
[6] Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index
Raslova, Katarina
Tamer, Soren Can
Clauson, Per
Karl, Diane
CLINICAL DRUG INVESTIGATION, 2007, 27 (04) : 279 - 285
[7] Detemir as a once-daily basal insulin in type 2 diabetes
Nelson, Scott E.
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2011, 3 : 27 - 37
[8] Switching patients with type 1 and type 2 diabetes on basal-bolus regimen from twice-daily NPH to once-daily insulin detemir leads to improved control and safety
Aczel, Stefan
Hansen, Jes B.
Tsur, Anat
DIABETES, 2007, 56 : A544 - A544
[9] Switching from basal-bolus therapy with NPH insulin to basal-bolus therapy with the analog insulin detemir improves glycemic control and reduces hypoglycemic episodes, without weight gain, in type 1 and type 2 diabetes patients: Results from German subgroup of the PREDICTIVE study
Ruhnau, Klaus-Juergen
Hansen, Jes B.
Dornhorst, Anne
DIABETES, 2006, 55 : A133 - A133
[10] Insulin detemir achieves lower, less variable fasting glucose and a reduced risk of nocturnal hypoglycaemia and weight gain compared to NPH insulin in basal bolus therapy of Japanese patients with type 1 diabetes
Kobayashi, M.
Iwamoto, Y.
Kawamori, R.
Tajima, N.
Nishida, T.
Kaku, K.
DIABETOLOGIA, 2006, 49 : 608 - 609

← 1 2 3 4 5 →